Performance Evaluation of Montelukast Pediatric Formulations: Part I—Age-Related In Vitro Conditions-Reference-Cited by-同舟云学术

Performance Evaluation of Montelukast Pediatric Formulations: Part I—Age-Related In Vitro Conditions

Published:2022-01 Issue:1 Volume:24 Page:
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Guimarães Mariana,Somville Pascal,Vertzoni Maria,Fotaki Nikoletta^ORCID

Abstract

AbstractThis study aimed to explore the potential of biopharmaceutics in vitro tools to predict drug product performance in the pediatric population. Biorelevant dissolution set-ups were used to predict how age and medicine administration practices affect the in vitro dissolution of oral formulations of a poorly water-soluble compound, montelukast. Biorelevant age-appropriate dissolution studies of Singulair® (granules and chewable tablets) were conducted with the µDISS profiler™, USP 4 apparatus, USP 2 apparatus, and mini-paddle apparatus. Biorelevant simulating fluids representative of adult and pediatric conditions were used in the dissolution studies. The biorelevant dissolution conditions were appropriately selected (i.e. volumes, transit times, etc.) to mimic the gastrointestinal conditions of each of the subpopulations tested. Partial least squares regression (PLS-R) was performed to understand the impact of in vitro variables on the dissolution of montelukast. Montelukast dissolution was significantly affected by the in vitro hydrodynamics used to perform the dissolution tests (µDISS profiler™: positive effect); choice of simulation of gastric (negative effect) and/or intestinal conditions (positive effect) of the gastrointestinal tract; and simulation of prandial state (fasted state: negative effect, fed state: positive effect). Age-related biorelevant dissolution of Singulair® granules predicted the in vivo effect of the co-administration of the formulation with applesauce and formula in infants. This study demonstrates that age-appropriate biorelevant dissolution testing can be a valuable tool for the assessment of drug performance in the pediatric population. Graphical Abstract

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

https://link.springer.com/content/pdf/10.1208/s12248-021-00661-2.pdf

Reference45 articles.

1. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15(1):11–22. https://doi.org/10.1023/a:1011984216775.

2. Fotaki N, Vertzoni M. Biorelevant dissolution methods and their applications in in vitro-in vivo correlations for oral formulations. Open Drug Deliv J. 2010;4(2):2–13. https://doi.org/10.2174/1874126601004010002.

3. Butler J, Hens B, Vertzoni M, Brouwers J, Berben P, Dressman JB, et al. In vitro models for the prediction of in vivo performance of oral dosage forms: recent progress from partnership through the IMI OrBiTo collaboration. Eur J Pharm Biopharm. 2019;136:70–83. https://doi.org/10.1016/j.ejpb.2018.12.010.

4. Batchelor HK, Kendall R, Desset-Brethes S, Alex R, Ernest TB. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients. Eur J Pharm Biopharm. 2013;85(3 Pt B):833–42. https://doi.org/10.1016/j.ejpb.2013.04.015.

5. Guimarães M, Statelova M, Holm R, Reppas C, Symilllides M, Vertzoni M, et al. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products – a PEARRL review. J Pharm Pharmacol. 2019;71(4):603–42. https://doi.org/10.1111/jphp.12955.